莫美替尼对比达那唑治疗骨髓纤维化伴贫血有症状患者(MOMENTUM):一项国际、双盲、随机、对照、3期研究结果
MOMENTUM是一项国际、双盲、随机、对照、3期研究,在21个国家107个中心纳入195例确诊原发性骨髓纤维化或真性红细胞增多症后或原发性血小板增多症后骨髓纤维化、年龄≥18岁、已接受JAK抑制剂治疗且有症状伴贫血的中危或高危患者,按2:1随机分配至莫美替尼200 mg口服每日一次加达那唑安慰剂组(130例)或达那唑300 mg口服每日两次加莫美替尼安慰剂组(65例),分层因素包括总症状评分(<22 vs ≥22)、脾脏大小(<12 cm vs ≥12 cm)、随机化前8周输注红细胞或全血单位数(0单位 vs 1-4单位 vs ≥5单位)和研究中心。主要终点为第24周骨髓纤维化症状评估表(MFSAF)总症状评分应答率(定义为第24周末前28天平均MFSAF总症状评分较基线降低≥50%)。结果显示莫美替尼组应答率显著高于达那唑组(32/130[25%] vs 6/65[9%];率差16%[95%CI 6-26],p=0.0095)。莫美替尼组和达那唑组最常见的≥3级治疗中出现的不良事件为实验室检查血液学异常:贫血(79/130[61%] vs 49/65[75%])和血小板减少(36/130[28%] vs 17/65[26%]);最常见的非血液学≥3级治疗中出现的不良事件为急性肾损伤(4/130[3%] vs 6/65[9%])和肺炎(3/130[2%] vs 6/65[9%])
要点
- 在已接受JAK抑制剂治疗、伴贫血的中危或高危骨髓纤维化患者中,莫美替尼200 mg口服每日一次对比达那唑300 mg口服每日两次,第24周MFSAF总症状评分应答率(较基线降低≥50%)为25%(32/130)vs 9%(6/65),率差16%(95%CI 6-26),p=0.0095。
- 莫美替尼组和达那唑组最常见的≥3级治疗中出现的不良事件为实验室检查血液学异常:贫血(61%[79/130] vs 75%[49/65])和血小板减少(28%[36/130] vs 26%[17/65])。
- 莫美替尼组和达那唑组最常见的非血液学≥3级治疗中出现的不良事件为急性肾损伤(3%[4/130] vs 9%[6/65])和肺炎(2%[3/130] vs 9%[6/65])。
- 作者认为,莫美替尼对比达那唑在骨髓纤维化相关症状、贫血指标和脾脏应答方面取得有临床意义的改善,且安全性良好。
- 该研究纳入18岁及以上、确诊原发性骨髓纤维化或真性红细胞增多症后或原发性血小板增多症后骨髓纤维化、已接受JAK抑制剂治疗且有症状伴贫血的中危或高危患者。
适用人群与场景
- 年龄≥18岁,确诊原发性骨髓纤维化或真性红细胞增多症后或原发性血小板增多症后骨髓纤维化。
- 已接受JAK抑制剂治疗、有症状且伴贫血的中危或高危患者。
诊断标准与关键阈值
- 主要终点应答定义:第24周末前28天平均MFSAF总症状评分较基线降低≥50%。
- 分层因素:总症状评分(<22 vs ≥22)、脾脏大小(<12 cm vs ≥12 cm)、随机化前8周输注红细胞或全血单位数(0单位 vs 1-4单位 vs ≥5单位)和研究中心。
处置流程与药物剂量
- 莫美替尼组:莫美替尼200 mg口服每日一次,加达那唑安慰剂。
- 达那唑组:达那唑300 mg口服每日两次,加莫美替尼安慰剂。
- 随机化按2:1分配至莫美替尼组或达那唑组。
研究设计与关键结果
- 研究类型:国际、双盲、随机、对照、3期研究;在21个国家107个中心纳入195例患者,随机分配至莫美替尼组(130例[67%])或达那唑组(65例[33%]),在2020年4月24日至2021年12月3日的24周随机治疗期内接受研究治疗。
- 主要终点:第24周MFSAF总症状评分应答率(较基线降低≥50%)莫美替尼组32/130(25%) vs 达那唑组6/65(9%),率差16%(95%CI 6-26),p=0.0095。
- ≥3级治疗中出现的不良事件(实验室检查血液学异常):贫血莫美替尼组79/130(61%) vs 达那唑组49/65(75%);血小板减少36/130(28%) vs 17/65(26%)。
- ≥3级治疗中出现的不良事件(非血液学):急性肾损伤莫美替尼组4/130(3%) vs 达那唑组6/65(9%);肺炎3/130(2%) vs 6/65(9%)。
证据类型、等级与局限
- 证据类型:国际、双盲、随机、对照、3期研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,莫美替尼对比达那唑在骨髓纤维化相关症状、贫血指标和脾脏应答方面取得有临床意义的改善,且安全性良好;这些发现支持莫美替尼未来作为骨髓纤维化患者的有效治疗,尤其是伴贫血的患者。
指南或共识出处
- MOMENTUM研究,ClinicalTrials.gov注册号NCT04173494,资助方Sierra Oncology,发表于Lancet。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.
METHODS: MOMENTUM is an international, double-blind, randomised, controlled, phase 3 study that enrolled patients at 107 sites across 21 countries worldwide. Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Patients were randomly assigned (2:1) to receive momelotinib (200 mg orally once per day) plus danazol placebo (ie, the momelotinib group) or danazol (300 mg orally twice per day) plus momelotinib placebo (ie, the danazol group), stratified by total symptom score (TSS; <22 vs ≥22), spleen size (<12 cm vs ≥12 cm), red blood cell or whole blood units transfused in the 8 weeks before randomisation (0 units vs 1-4 units vs ≥5 units), and study site. The primary endpoint was the Myelofibrosis Symptom Assessment Form (MFSAF) TSS response rate at week 24 (defined as ≥50% reduction in mean MFSAF TSS over the 28 days immediately before the end of week 24 compared with baseline). MOMENTUM is registered with ClinicalTrials.gov, number NCT04173494, and is active but not recruiting.
FINDINGS: 195 patients were randomly assigned to either the momelotinib group (130 [67%]) or danazol group (65 [33%]) and received study treatment in the 24-week randomised treatment period between April 24, 2020, and Dec 3, 2021. A significantly greater proportion of patients in the momelotinib group reported a 50% or more reduction in TSS than in the danazol group (32 [25%] of 130 vs six [9%] of 65; proportion difference 16% [95% CI 6-26], p=0·0095). The most frequent grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were haematological abnormalities by laboratory values: anaemia (79 [61%] of 130 vs 49 [75%] of 65) and thrombocytopenia (36 [28%] vs 17 [26%]). The most frequent non-haematological grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were acute kidney injury (four [3%] of 130 vs six [9%] of 65) and pneumonia (three [2%] vs six [9%]).
INTERPRETATION: Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in myelofibrosis-associated symptoms, anaemia measures, and spleen response, with favourable safety. These findings support the future use of momelotinib as an effective treatment in patients with myelofibrosis, especially in those with anaemia.
FUNDING: Sierra Oncology.
参考来源
- Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023. PMID: 36709073. doi:10.1016/S0140-6736(22)02036-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。